Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 67-76

  Maddrey, Willis C ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Interferon; Ribavirin; Safety; Tolerability

Indexed keywords

ALPHAN1 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEPATITIS C; HUMAN; LEUKOCYTE COUNT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032895782     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499
2. McHutchison JG, Gordon SC, Schiffer, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
3. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-1432
4. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506
5. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510
6. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-789
7. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-277
8. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-243
9. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-706
10. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11(suppl4):S750-S761
11. Neyts J, Meerbach A, McKenna P, De Clercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996;30:125-132
12. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26: 473-477
13. Reichard O, Norkrans G, Fryden A, Braconier J, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-86
14. Ferm VH, Wilhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978;17:93-101
15. Kochhar DM, Penner JD, Knudsen TB. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 1980;52:99-112
16. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10:281-291
17. Maddrey WC. New perspectives on the safety of combination interferon alfa-2b/ribavirin therapy for chronic hepatitis C. Hepatology In Press
18. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994;10:115-150
19. Lertora JJ, Rege AB, Lacour JT, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991;50:442-449
20. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 1990;22:379-383
21. Shulman NR. Assessment of hematological effects of ribavirin in humans. In: Smith RA, Knight V, Smith JAD, eds. Clinical Application of Ribavirin. New York, NY: Academic Press; 1984:79-92
22. Weisz K, Dreiswirth S, McMeeking M, et al. Erythropoietin use for ribavirin/interferon induced anemia in patients with hepatitis C [abstract]. Hepatology 1998;28:288A. Abstract 501
23. Dusheiko G. Side effects of alfa interferon in chronic hepatitis C. Hepatology 1997;26(suppl 1, pt 3):112S-121S
24. Fattovich G, Guistina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47
25. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-243
26. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41:672-676
27. Wiranowska M, Wilson TC, Thompson K, Prockop LD. Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier. J Interferon Res 1989;9:353-362.
28. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med 1993;329:1246-1253
29. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol 1995;41:534-538
30. Rothwell NJ, Luheshi G, Toulmond S. Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacol Ther 1996;69:85-95.
31. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993;88:760-761.
32. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-a therapy. Semin Oncol 1998;1:39-47
33. Data on File. Integrated Summary of Safety. Kenilworth, NJ: Schering-Plough Corporation; 1998:1-123
34. Data on File. New Drug Application Supplement. NDA 20-903. Kenilworth, NJ: Schering-Plough Corporation; 1998:47